Stock analysts at StockNews.com started coverage on shares of Ampio Pharmaceuticals (NYSE:AMPE – Get Free Report) in a note issued to investors on Monday. The firm set a “sell” rating on the stock.
Ampio Pharmaceuticals Trading Down 8.3 %
AMPE opened at $0.32 on Monday. The firm has a market cap of $364,335.00, a P/E ratio of -0.03 and a beta of 1.95. Ampio Pharmaceuticals has a 12 month low of $0.14 and a 12 month high of $8.30. The stock has a 50-day moving average of $1.19 and a 200 day moving average of $1.87.
Ampio Pharmaceuticals (NYSE:AMPE – Get Free Report) last released its quarterly earnings results on Wednesday, March 27th. The company reported ($2.48) EPS for the quarter.
Ampio Pharmaceuticals Company Profile
Ampio Pharmaceuticals, Inc, a biopharmaceutical company, develops therapies for the treatment of osteoarthritis of the knee (OAK) in the United States. It develops OA-201, a small molecule formulation for the treatment of OAK pain. The company is headquartered in Englewood, Colorado.
Read More
- Five stocks we like better than Ampio Pharmaceuticals
- What Is WallStreetBets and What Stocks Are They Targeting?
- Snap Crackles and Pops on Surprise Profit and Raised Guidance
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- MarketBeat Week in Review – 4/22 – 4/26
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- 3 Stocks Leading the U.S. Agriculture Comeback
Receive News & Ratings for Ampio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ampio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
